RayKnowChina Research Map
Shortlist

Enrolling by invitationCoronary heart diseaseN/A

Registered title, quoted from ClinicalTrials.gov

A Coronary Computed Tomography Angiography-guided Intervention for High Risk Cardiovascular Disease Population in Rural China

An open trial on coronary heart disease, registered on ClinicalTrials.gov. Led by Second Affiliated Hospital of Harbin Medical University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Second Affiliated Hospital of Harbin Medical University哈尔滨医科大学附属第二医院HarbinHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07416344, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 40 years to 75 years; sex: all

    Registered eligibility fields

  2. End-stage diseases such as cirrhosis decompensation, with life expectancy <3 years

    Exclusion criterion 7

  3. eGFR <30 mL/min/1.73m\^2

    Exclusion criterion 12

    Platelet count <100×10\^9/L

    Exclusion criterion 13

  4. Pregnant or breastfeeding, planning to become pregnant within the next 3 years

    Exclusion criterion 11

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; earlier treatment; day-to-day activity level; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07416344, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

Inclusion criteria of study villages:

  • Administrative villages
  • The village has no plans to merge with other villages within 3 years
  • The village is at least 2 kilometers away from other participating villages
  • The village has a sufficient number of study participants
  • The village is able to cooperate with the implementation of the study

Inclusion criteria of study participants:

  • Men or women aged between 40 and 75 years
  • Live stably in the province where the study is conducted and no intention to migrate within next 3 years
  • Not participating in other clinical trials
  • Meet any of the following:

(1)Low-Density Lipoprotein Cholesterol (LDL-C) ≥ 4.9 mmol/L or Total Cholesterol (TC) ≥ 7.2 mmol/L (2)Diabetes mellitus (3)Chronic Kidney Disease (CKD) Stage 3-4: estimated Glomerular Filtration Rate (eGFR) 15-59 mL/min/1.73m\^2 (4)With a history of hypertension and 3 risk factors, combined with LDL-C ≥ 1.8 mmol/L or TC ≥ 3.1 mmol/L [Risk factors (assessed pre-intervention): smoking, low HDL-C, male ≥ 45 years old or female ≥ 55 years old] (5)With a history of hypertension and 2 risk factors, combined with LDL-C ≥ 2.6 mmol/L or TC ≥ 4.1 mmol/L [Risk factors (assessed pre-intervention): smoking, low HDL-C, male ≥ 45 years old or female ≥ 55 years old] 5. Sign the informed consent

Exclusion Criteria:

  • Unwillingness or inability to undergo coronary CTA examination (e.g., previous history of severe contrast allergy, claustrophobia, or inability to cooperate with scanning and breath-holding for physical reasons in study participants)
  • Typical angina symptoms, known coronary artery disease, or other major atherosclerotic cardiovascular disease
  • Known cerebrovascular disease (e.g., cerebral hemorrhage, cerebral infarction, etc. )
  • Prior invasive or non-invasive coronary angiography within the last 5 years
  • Known familial hypercholesterolemia or other inherited disorders of lipid metabolism requiring lipid-lowering therapy
  • Presence of active bleeding or diseases with a very high risk of bleeding (e.g., active peptic ulcer disease, gastrointestinal pathologies with increased risk of bleeding, hematologic disorders with increased risk of bleeding, etc.)
  • End-stage diseases such as cirrhosis decompensation, with life expectancy <3 years
  • Have a malignant tumor
  • Intolerance of all statins
  • Lipid-lowering treatment for >2 years
  • Pregnant or breastfeeding, planning to become pregnant within the next 3 years
  • eGFR <30 mL/min/1.73m\^2
  • Platelet count <100×10\^9/L
  • Poor compliance, unable to cooperate with study investigators
  • Investigators consider unsuitable for participants selected for this study

Quoted from ClinicalTrials.gov, NCT07416344, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07416344, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07416344